Branded products in diabetes care commercialized by Sanofi under an exclusive worldwide license.
Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi.
Lixisenatide is available as Adlyxin® in the U.S. and is approved as Lyxumia® in more than 60 countries worldwide and marketed in over 40 by Sanofi. Commercial launches include most EU countries, Japan, Brazil, Mexico, India and the U.S. as of January 2017. Adlyxin®/Lyxumia® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.